Drug name - Belbuca

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief Dec, 2032

(10 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Treatment: Treatement of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 0.075MG BASE FILM;BUCCAL Prescription
EQ 0.15MG BASE FILM;BUCCAL Prescription
EQ 0.3MG BASE FILM;BUCCAL Prescription
EQ 0.45MG BASE FILM;BUCCAL Prescription
EQ 0.6MG BASE FILM;BUCCAL Prescription
EQ 0.75MG BASE FILM;BUCCAL Prescription
EQ 0.9MG BASE FILM;BUCCAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.